New data show that use of CAPHOSOL® (http://www.caphosol.com/), an advanced oral electrolyte solution, resulted in both favorable impact on rates and severity of oral mucositis (OM) in cancer patients undergoing chemotherapy and radiation therapy.

ORLANDO, FL (UroToday.com) - CG0070 is a replication-competent adenovirus modified to replicate preferentially in retinoblastoma pathway-defective cancers and to express granulocyte-macrophage colony-stimulating factor (GM-CSF). This study initially assessed escalating single dose intravesical (IV) administration of CG0070, and reported a tolerable safety profile with signs of anti-tumor activity.

Heart disease is the nation’s number one killer for women. But, the well-known heart attack symptoms acute pain, tightness, burning and a dull ache in the chest describe what men typically experience during an attack. For many women the signs of a heart attack are completely different and can go unrecognized. Women tend to ignore signs of heart attack, thus increasing the likelihood of tragic consequences.

Research that has yielded success in controlling certain errors in gene expression as a safer and more effective alternative to conventional drugs has won for Prof. Hermona Soreq, dean of the Faculty of Science at the Hebrew University of Jerusalem, one of this year’s Kaye Innovation Awards. The awards, presented annually during the Hebrew University’s Board of Governors meeting, were presented during the 71st meeting of the board. The concept behind Prof.

Californians hospitalized with community-acquired pneumonia (CAP) could more than double their chances of survival if they are treated at one of the top-rated hospitals, according to a newly released report from the Office of Statewide Health Planning and Development (OSHPD), “Community Acquired Pneumonia: Hospital Outcomes in California, 2003-2005.

International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas (liver tumours) to live 40% more on average compared to those not taking the drug. The study, led by the Barcelona Hospital Clinic, will be shortly published in the New England Journal of Medicine.

Surgery has been done inside some adults’ hearts while the heart is still beating, avoiding the need to open the chest, stop the heart and put patients on cardiopulmonary bypass. But to perform intricate beating-heart operations in babies with congenital heart disease or do beating-heart complex repairs in adults, surgeons need fast, highly sophisticated real-time imaging that allows them to see depth.

The United Health Foundation and Congressman Elijah E. Cummings (D-Md.) announced a $300,000 grant from the Foundation to establish a model “program in dental excellence” at Howard University’s College of Dentistry that will expand access to quality dental care for low-income children and their families who reside in Washington, D.C. and Prince George’s County.

Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice. The treatment will involve transfusing specific white blood cells, called granulocytes, from select donors, into patients with advanced forms of cancer.

Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), has announced the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.